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total of 731 participants had the inclusion criteria, mean age was 45 years old 
(SD= 6.3). Seventy six percent (n= 490) reported being affected of a skin psoria-
sis, 1.64% (n= 12) by psoriatic arthritis, and 31.33% (n= 229) by both types. Items 
causing higher social impact were those related to personal exposure in public 
places (scale 0-10: 6.08) and participation in sport activities (scale 0-10: 5.68); Less 
than half of participants reported managing these two issues successfully. Social 
impact of psoriasis was higher in younger participants, living alone, or not mar-
ried, unemployed, and with less household income (p< 0,001). ConClusions: 
Impact of psoriasis might be assessed and requires clinical, social actions and 
emotional support to ensure patients with psoriasis having the best care. Specific 
population groups need specific health care interventions to avoid harms of social-
ization linked to psoriasis.
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objeCtives: To examine the association between inflammation reduction and 
visual function response in subjects with active NIU of the posterior segment who 
received intravitreal sirolimus in SAKURA Study 1, a phase 3, double-masked, 
multinational study. Methods: Visual function was assessed via best corrected 
visual acuity (BCVA) and the National Eye Institute Visual Function Questionnaire 
(NEI-VFQ-25). Principal component analysis was used to identify 3 visual func-
tion measures. Minimal clinically important differences (MCID) for the VFQ-25 
Composite and VFQ-25 Mental Health subscale scores were established based on 
the standard error of measurements of baseline scores. For BCVA, 2 ETDRS lines of 
improvement was used as a meaningful threshold. Response on any single meas-
ure was considered an overall visual function response. Anatomic vitreous haze 
(VH) response was defined as a VH score of 0 or 0.5+ at Month 5. Results: 347 sub-
jects were randomized 1:1:1 to every-other-month injections of intravitreal siroli-
mus 44 µg (active control), 440 µg, or 880 µg. Significantly more subjects in the 440 
µg group (52.6%) achieved an anatomic response compared with the 44 µg group 
(35.0%) (p= .008). When the MCID for the NEI-VFQ-25 Composite and Mental Health 
subscale scores were established at 4.3 and 11.7 points, respectively, the associa-
tion between anatomic and visual function response was statistically significant. 
In those achieving an anatomic response, a significant relationship was seen 
with all visual function response measures: VFQ-25 Composite score (OR= 2.234; 
p= .0004); VFQ-25 Mental Health subscale score (OR= 2.837; p< .0001); BCVA 2-line 
improvement (OR= 2.601; p= .0009), and overall visual function response (OR= 2.650; 
p< .0001). ConClusions: In SAKURA Study 1, the reduction of inflammation to a 
VH score of 0 or 0.5+ was significantly associated with improved visual function as 
measured by BCVA, VFQ-25 Composite, VFQ-25 Mental Health, and overall visual 
function responses. Thus, achieving a VH response of 0 or 0.5+ can be considered 
a patient-relevant outcome.
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objeCtives: Patient reported outcomes (PRO) are becoming useful tools for 
collecting and generating evidence for new medical products to show improve-
ments in health-related quality of life (HRQoL). Glaucoma is a chronic disease 
with high importance for patient HRQoL. The objective of this study was to review, 
analyze, and understand trends in the PRO instruments used in patients with 
Glaucoma. Methods: A systematic literature search for Glaucoma trials with 
PROs endpoints was undertaken for the databases Pubmed, Embase, Biosis, Google 
Scholar and Cochrane. Data was collected for the study size, interventions, year, 
PRO instrument and Resultsfor PROs. Analysis for conducted to identify trends 
in commonly used PRO instruments and categorize Resultsas positive, neutral 
or negative. Results: 31 studies with a total of 9819 patients were identified. In 
these studies there were eleven different PROs instruments were identified that 
were Glaucoma health perception index, Glaucoma quality of life questionnaire 
(Glau-QoL), Glaucoma utility index, Impact of vision impairment, Low vision qual-
ity of life questionnaire, National eye institute visual function index-19 items, 
National eye institute visual function index-51 items, Nursing home vision quality 
of life questionnaire, Quality of life and visual function questionnaire, Vision core 
module 1, and Vision quality of life index. The most commonly used instruments 
were Impact of vision impairment (used in 7 studies) and Low vision quality of life 
questionnaire (used in 4 studies). ConClusions: Patients with glaucoma have 
significant impairment in their QoL, hence collection of such data is important 
for new medical products. PRO instruments such as Impact of vision impairment 
and Low vision quality of life questionnaire have been commonly used to generate 
evidence to show which therapies improve patient QoL.
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objeCtives: Infantile hemangioma (IH) is a benign neoplasm, resulting from 
vascular proliferation, with an estimated incidence of 3 to 10% within the 
first year of birth. While, in most cases, IH involute spontaneously by the age 
of 7 years, some hemangiomas (i.e. life or function-threatening IH, risk of 
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objeCtives: Alexithymia is the inability to describe and project emotions in the self. 
Our objective was to assess the association between alexithymia in psoriasis (PSO) 
and loss of work productivity and activity in PSO patients. Methods: EPIDEPSO 
(NCT01964443) is a 12-month observational, international study, to investigate 
alexithymia and other psychosocial comorbidities in PSO with disease duration 
≤ 10 years. Presence of alexithymia was defined as a score of ≥ 61 on the 20-item 
Toronto Alexithymia Scale. Work productivity and activity were assessed using the 
Work Productivity and Activity Impairment Questionnaire: PSO (WPAI-PSO). Clinical 
assessments and patient-reported outcomes included the Psoriasis Area and Severity 
Index (PASI) and the Dermatology Life Quality Index (DLQI). Results: The data dis-
played are from baseline analyses. The prevalence of alexithymia was 39% (95% CI 
35−43%). Alexithymic patients had higher unemployment rates than non-alexithymic 
patients (48% vs 25%, p< 0.0001). WPAI-PSO Resultsamong employed patients showed 
comparable absenteeism between alexithymic and non-alexithymic patients, but 
more impairment at work (presenteeism) (29% vs 13%) and productivity loss (34% vs 
17%) was greater in alexithymic than non-alexithymic patients. In both employed 
and unemployed patients there was greater activity impairment among alexithymic 
patients (38% vs 20%, all p< 0.0001). In the overall population, patients with a PASI 
score > 10 showed more impairment at work (24% vs 15%), greater productivity loss 
(30% vs 18%) and greater activity impairment (36% vs 20%) than those with a PASI 
score ≤ 10 (all p< 0.01). Moderate correlations between DLQI and presenteeism (r= 0.56), 
productivity loss (r= 0.55) and activity impairment (r= 0.65, all p-values < 0.0001) were 
identified. ConClusions: In PSO patients, the inability to describe and project emo-
tions may have an impact on daily work productivity and activity. Our data indicate 
that there is a complex relationship between alexithymia, disease severity, and quality 
of life upon employment status and productivity.
PSS60
valIdatIon oF the SPanISh verSIon oF the urtIcarIa actIvIty Score 
(uaS) and ItS uSe over one Week (uaS7)
Balañá M1, Valero A2, Giménez Arnau A3, Ferrer M4, Jauregui I5, Ballesteros C1, on behalf of 
the study group of EVALUAS .1
1Novartis Farmacéutica S.A., Barcelona, Spain, 2Hospital Clinic, Barcelona, Spain, 3Hospital Mar, 
Barcelona, Spain, 4Clínica Universitaria de Navarra, Pamplona, Spain, 5Hospital de Basurto, 
Bilbao, Spain
objeCtives: To validate the Spanish version of the UAS, the most widely used 
patient-reported outcome measure for patients with chronic idiopathic urti-
caria (CIU), and its administration over 7 consecutive days (UAS7). Methods: 
Observational, prospective, multicentre study in adult patients with CIU. The UAS 
has 2 items (intensity of pruritus and number of hives, scored 0-3) and ranges from 
0-6 (lowest to highest disease activity). The UAS7 is the sum of UAS over 7 consecu-
tive days. Both scales were completed at baseline and after 6 weeks, together with 
health-related quality of life (CU-Q2oL and EQ-5D) and disease severity (Clinician 
(CRS) and Patient Rating Scale (PRS); Clinician (CRSC) and Patient Rating Scale of 
Change (PRSC)) questionnaires. Results: 166 patients were included. Overall, 
< 16% of responses were missing or non-valid. Maximum floor and ceiling effects 
were 19.3% and 6.0%, respectively. Internal consistency was good (Cronbach’s 
alpha:UAS= 0.68 [baseline] and 0.83 [6 weeks]; UAS7= 0.83 in both visits) and test-
retest reliability was adequate (intraclass correlation coefficients of 0.65 (UAS) and 
0.84 (UAS7) in stable patients (n= 37 and 49, respectively)). Known-groups valid-
ity was supported by significantly different scores between severity subgroups 
according to CRS and PRS (P< 0.001 in all cases). Good construct validity was also 
observed, with moderate/strong correlations with the CU-Q2oL scores (r= 0.37-0.59), 
and weak correlations with the EQ-5D visual analogue scale (r= −0.15-(−0.30)) and 
index (r= −0.15-(−0.28)). Sensitivity to change was good, with large effect sizes (≥ 0.8) 
for patients with ≥ 3 points-change in severity (CRSC or PRSC). The minimally impor-
tant difference for the UAS7 ranged from 4-5, less than reported for the English 
version (9.5-10.5). ConClusions: The Spanish versions of UAS and UAS7 scales are 
valid, applicable and reliable tools to assess disease control in the clinical practice 
in patients with CIU. A 4-5 point change on the Spanish UAS7 might be interpreted 
as an important difference.
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objeCtives: Psoriasis is a chronic skin disease that causes an important physical, 
psychological, and economic impact on the people affected. However social impact 
has not been studied until recently. The objective of this study was to examine 
the social impact of psoriasis as reported by patients. Methods: Data came from 
the study “Acción 2014”, an online survey carried out by the Spanish association 
of patients and their families affected by Psoriasis and psoriatic arthritis (“Acción 
Psoriasis”), the study took place from December 2013 to April 2014. We included 
all psoriatic Spanish participants, and we examined the set of 13 items referred to 
the social impact of psoriasis using a Rasch model. This implied studying the scale 
functioning, item fit, item dependency, and the unidimensionality assumption. 
The units of the Rasch (logits) were transformed into a 0-10 scale. We analysed 
overall differences between groups of patients with ANOVA tests. Results: A 
